217 related articles for article (PubMed ID: 30212404)
1. Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
Koss CA; Liu AY; Castillo-Mancilla J; Bacchetti P; McHugh C; Kuncze K; Morrow M; Louie A; Seifert S; Okochi H; MaWhinney S; Gandhi M; Anderson PL
AIDS; 2018 Sep; 32(15):2189-2194. PubMed ID: 30212404
[TBL] [Abstract][Full Text] [Related]
2. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
Koss CA; Hosek SG; Bacchetti P; Anderson PL; Liu AY; Horng H; Benet LZ; Kuncze K; Louie A; Saberi P; Wilson CM; Gandhi M
Clin Infect Dis; 2018 Jan; 66(2):213-219. PubMed ID: 29020194
[TBL] [Abstract][Full Text] [Related]
5. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
[TBL] [Abstract][Full Text] [Related]
6. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
7. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
[TBL] [Abstract][Full Text] [Related]
8. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
9. Nondaily preexposure prophylaxis for HIV prevention.
Anderson PL; García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
[TBL] [Abstract][Full Text] [Related]
10. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
11. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
[TBL] [Abstract][Full Text] [Related]
12. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
13. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
14. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
[TBL] [Abstract][Full Text] [Related]
15. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
17. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
18. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
19. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
